Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 9/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.48 |
| ▸ | CYP26A1 | O43174 | 4/20 | 0.43 |
| ▸ | HTR1A | P08908 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28733931 | 0.86 | CYP19A1 (0.59) | CYP19A1CYP26A1HTR1ASIGMAR1 | |
| SCHEMBL10686519 | 0.86 | CYP19A1 (0.59) | CYP19A1CYP26A1HTR1ASIGMAR1 | |
| SCHEMBL29679345 | 0.86 | CYP19A1 (0.59) | CYP19A1CYP26A1HTR1ASIGMAR1 | |
| SCHEMBL6825354 | 0.84 | CYP19A1 (0.73) | CYP19A1HTR1ASIGMAR1 | |
| SCHEMBL6827906 | 0.83 | CYP19A1 (0.76) | CYP19A1PDE4DCYP26A1 | |
| SCHEMBL9586682 | 0.77 | CYP19A1 (0.48) | CYP19A1PDE4DCYP26A1 | |
| SCHEMBL6822323 | 0.76 | CYP19A1 (0.76) | CYP19A1PDE4DCYP26A1SIGMAR1 | |
| SCHEMBL10686411 | 0.76 | CYP26A1 (0.61) | CYP19A1CYP26A1HTR1ASIGMAR1 | |
| SCHEMBL28733978 | 0.76 | CYP26A1 (0.61) | CYP19A1CYP26A1HTR1ASIGMAR1 | |
| SCHEMBL29679374 | 0.76 | CYP26A1 (0.61) | CYP19A1CYP26A1HTR1ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-03-15 | — | — | US | disclosed |
| WO-2011123674-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. (US) | 2011-10-06 | — | — | WO | disclosed |
| EP-0073663-B1 | THROMBOXANE SYNTHETASE INHIBITORS, PROCESSES FOR THEIR PRODUCTION, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Pfizer Limited (GB) | 1986-06-18 | — | — | EP | disclosed |
| US-4590200-A | NON-INHIBITION OF PROSTACYCLIN SYNTHETASE OR CYCLO-OXYGENASE | PFIZER INC. (US) | 1986-05-20 | — | — | US | disclosed |
| US-4496572-A | Benzo-fused thromboxane synthetase inhibitors | PFIZER INC. (US) | 1985-01-29 | — | — | US | disclosed |
| EP-0073663-A2 | Thromboxane synthetase inhibitors, processes for their production, and pharmaceutical compositions comprising them | Pfizer Limited (GB) | 1983-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | APP, BACE1, PSEN1 | CYP19A1 906/4885PDE4D 1032/4885CYP26A1 1273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.